Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia

Overview

Journal Cancer Discov

Specialty Oncology

Date 2016 Aug 19

PMID 27535106

Citations 140

Authors

Michael W M Kuhn

Evelyn Song

Zhaohui Feng

Amit Sinha

Chun-Wei Chen

Aniruddha J Deshpande

Monica Cusan

Noushin Farnoud

Annalisa Mupo

Carolyn Grove

Richard Koche

James E Bradner

Elisa de Stanchina

George S Vassiliou

Takayuki Hoshii

Scott A Armstrong

Affiliations

Soon will be listed here.

Abstract

Significance: MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1 AML. Combinatorial small-molecule inhibition has synergistic on-target activity and constitutes a novel therapeutic concept for this common AML subtype. Cancer Discov; 6(10); 1166-81. ©2016 AACR.See related commentary by Hourigan and Aplan, p. 1087This article is highlighted in the In This Issue feature, p. 1069.

Citing Articles

Design of Potent Menin-KMT2A Interaction Inhibitors with Improved ADME Properties and Reduced hERG Affinity.

Chapsal B, Kimbrough J, Bester S, Bergstrom A, Backos D, Campos B ACS Med Chem Lett. 2025; 16(2):224-233.

PMID: 39967615 PMC: 11831402. DOI: 10.1021/acsmedchemlett.4c00311.

Functions of the native NPM1 protein and its leukemic mutant.

Falini B, Sorcini D, Perriello V, Sportoletti P Leukemia. 2024; 39(2):276-290.

PMID: 39690184 DOI: 10.1038/s41375-024-02476-4.

Targeting chromatin modifying complexes in acute myeloid leukemia.

Schurer A, Glushakow-Smith S, Gritsman K Stem Cells Transl Med. 2024; 14(2).

PMID: 39607901 PMC: 11878770. DOI: 10.1093/stcltm/szae089.

Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities.

Vatapalli R, Rossi A, Chan H, Zhang J Epigenomics. 2024; 17(1):59-74.

PMID: 39601374 PMC: 11702999. DOI: 10.1080/17501911.2024.2430169.

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.

Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N Curr Oncol. 2024; 31(11):6632-6658.

PMID: 39590121 PMC: 11592437. DOI: 10.3390/curroncol31110490.

References

Deshpande A, Bradner J, Armstrong S . Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012; 33(11):563-70. PMC: 4034385. DOI: 10.1016/j.it.2012.06.002. View

Krivtsov A, Twomey D, Feng Z, Stubbs M, Wang Y, Faber J . Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442(7104):818-22. DOI: 10.1038/nature04980. View

Yokoyama A, Cleary M . Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008; 14(1):36-46. PMC: 2692591. DOI: 10.1016/j.ccr.2008.05.003. View

Daigle S, Olhava E, Therkelsen C, Basavapathruni A, Jin L, Boriack-Sjodin P . Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013; 122(6):1017-25. PMC: 3739029. DOI: 10.1182/blood-2013-04-497644. View

Yokoyama A, Somervaille T, Smith K, Rozenblatt-Rosen O, Meyerson M, Cleary M . The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005; 123(2):207-18. DOI: 10.1016/j.cell.2005.09.025. View

Wang G, Pasillas M, Kamps M . Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood. 2005; 106(1):254-64. PMC: 1895124. DOI: 10.1182/blood-2004-12-4664. View

Deshpande A, Chen L, Fazio M, Sinha A, Bernt K, Banka D . Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013; 121(13):2533-41. PMC: 3612861. DOI: 10.1182/blood-2012-11-465120. View

Mupo A, Celani L, Dovey O, Cooper J, Grove C, Rad R . A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013; 27(9):1917-20. PMC: 3768110. DOI: 10.1038/leu.2013.77. View

Ernst P, Fisher J, Avery W, Wade S, Foy D, Korsmeyer S . Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell. 2004; 6(3):437-43. DOI: 10.1016/s1534-5807(04)00061-9. View

10.

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

11.

Shi J, Wang E, Milazzo J, Wang Z, Kinney J, Vakoc C . Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015; 33(6):661-7. PMC: 4529991. DOI: 10.1038/nbt.3235. View

12.

Huang J, Gurung B, Wan B, Matkar S, Veniaminova N, Wan K . The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature. 2012; 482(7386):542-6. PMC: 3983792. DOI: 10.1038/nature10806. View

13.

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

14.

Klaus C, Iwanowicz D, Johnston D, Campbell C, Smith J, Moyer M . DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014; 350(3):646-56. DOI: 10.1124/jpet.114.214577. View

15.

Mishra B, Zaffuto K, Artinger E, Org T, Mikkola H, Cheng C . The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep. 2014; 7(4):1239-47. PMC: 4120120. DOI: 10.1016/j.celrep.2014.04.015. View

16.

Falini B, Brunetti L, Martelli M . Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1180-2. DOI: 10.1056/NEJMc1509584. View

17.

Giampaolo A, Sterpetti P, Bulgarini D, Samoggia P, Pelosi E, Valtieri M . Key functional role and lineage-specific expression of selected HOXB genes in purified hematopoietic progenitor differentiation. Blood. 1994; 84(11):3637-47. View

18.

Kuhn M, Hadler M, Daigle S, Koche R, Krivtsov A, Olhava E . MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 2015; 100(5):e190-3. PMC: 4420229. DOI: 10.3324/haematol.2014.115337. View

19.

Sauvageau G, Lansdorp P, Eaves C, Hogge D, Dragowska W, Reid D . Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A. 1994; 91(25):12223-7. PMC: 45409. DOI: 10.1073/pnas.91.25.12223. View

20.

Gaidzik V, Schlenk R, Paschka P, Stolzle A, Spath D, Kuendgen A . Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013; 121(23):4769-77. DOI: 10.1182/blood-2012-10-461624. View